
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Miami, Fla. - The challenge in neonatal dermatology is that pediatricians who commonly see various skin conditions in infants often lack the training and knowledge to respond to the skin eruptions, according to the head of pediatric dermatology at the Phoenix Children's Hospital.